Health
Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%
JINAN, China, Dec. 6, 2023 /PRNewswire/ -- Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster pr...
2023-12-06 16:55
1989
Koselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas
KUALA LUMPUR, Malaysia, Dec. 6, 2023 /PRNewswire/ -- AstraZeneca's Koselugo (selumetinib)is now available in Malaysia as a monotherapy for the treatment of paediatric patients three years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas...
2023-12-06 16:46
1934
The Grand Opening of River Cam Dermatology Centre and River Cam Nutrition Center (Shatin) Amalgamates Ancient Chinese Medicine Skin Care Wisdom and Nutrition Science
HONG KONG, Dec. 6, 2023 /PRNewswire/ -- River Cam Medical Group announced the grand opening of the River Cam Dermatology Centre and River Cam Nutrition Centre (the Centre) on 29th November 2023. Located on the 7th Floor, Citylink Plaza, Shatin,Hong Kong, the Centre boasts a facial acupuncture tre...
2023-12-06 10:43
1673
GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
* To commence operation by 2027…with max. 400K liters of plasma production capacity per annum * The first step towards localization of Indonesia's critical medical product YONGIN,South Korea, Dec. 5, 2023 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, announced onDece...
2023-12-06 08:56
1853
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-12-06 08:16
3608
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 6, 2023 /PRNewswire/ --Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeuti...
2023-12-06 01:01
2183
The 2023 Investor Open Day of Zylox-Tonbridge was successfully held
HANGZHOU, China, Dec. 5, 2023 /PRNewswire/ -- On November 29th, the 2023 Investor Open Day of Zylox-Tonbridge ("2190. HK", hereinafter referred to as "the Company") was successfully held in Hangzhou, China. The event attracted more than 200 online and offline investors and securities analysts wo...
2023-12-05 22:22
4052
Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis
* Combines generative AI, machine learning and computer-aided drug-design to increase the success rate of new drugs and therapies * Virtually screens compounds from a universe of >60 billion chemical targets and evaluates synthesis routes for safer, cost-effective, higher-yield drug manufactu...
2023-12-05 21:00
1624
Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023
First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023 /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of its bispecific IO drug, cadonilimab (a PD-1/CTLA-4...
2023-12-05 21:00
1419
inQB8 Medical Technologies LLC and Peijia Medical Limited Report Successful First-in-Human (FIH) Implantation of MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System in The United States of America
WINCHESTER, Mass. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ -- inQB8 Medical Technologies LLC (inQB8), in partnership with Peijia Medical Limited (Peijia, (9996.HK)),announced that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve (TTV) in a patient suffering from torrenti...
2023-12-05 21:00
1916
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
--The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjects --The protocol of Phase III clinical trial has been agreed by Center for Drug Evaluation, National Medical Products Administration and obtained the approval from Institutional Review Board of Hu...
2023-12-05 16:50
2377
J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023
SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that
early results of the Phase 1/2 study of its novel, orally administered 4th
generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference
held inSingapore from 1st to 3rd December 2023.
2023-12-05 15:16
1383
Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk Research and Drug Development
New AI-enabled, integrated workflow provides pharma and biotech companies with comprehensive R&D insights to help minimize late-stage failures during clinical trials LONDON, Dec. 5, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intellig...
2023-12-05 15:00
1373
"JUNG KWAN JANG Red Ginseng Oil RXGIN Clean," Red Ginseng Oil, Gains Popularity in Korea for Excellent Effects in Improving BPH
SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- In August, clinical research results demonstrating the safe and effective improvement of benign prostatic hyperplasia (BPH) symptoms through the consumption of red ginseng oil were published in the prestigious international academic journalThe Worl...
2023-12-05 07:00
2436
Insilico Medicine Announces First-in-Human Study for Orally PHD Inhibitor ISM5411 for Inflammatory Bowel Disease (IBD)
* ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes. * ISM5411 is Insilico Medicine's fifth AI-driven drug program to enter clinical trials, with the first dose of healthy subjects completed inAustralia. ...
2023-12-05 06:00
1912
Ubie's AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships
Ubie, a trailblazing AI-driven healthcare company, has achieved a new milestone with its AI Symptom Checker, surpassing 2 million uses in the U.S. in just over a year. Leveraging this expanding user engagement, Ubie is advancing its partnerships with pharmaceutical companies to promote early dise...
2023-12-05 00:00
1496
Pioneering health innovations at China Int'l Supply Chain Expo
BEIJING, Dec. 4, 2023 /PRNewswire/ -- This is a report from China.org.cn about health innovations at China Int'l Supply Chain Expo:   At a dental clinic at the China Int'l Supply Chain Expo, you can take advantage of a free dental check. The 360° view allows you to see all a...
2023-12-04 22:20
1471
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration (FDA) has granted Investiga...
2023-12-04 21:50
1401
Technoderma Medicines Completes Phase 1 Dose Escalation Clinical Trial of TDM-180935 for Atopic Dermatitis
CHENGDU, China, Dec. 4, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment for Atopic Dermatitis (AD). This first cl...
2023-12-04 21:13
1348
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt,Germany. Under the terms of the agreement, Merck will be granted an exclusive licens...
2023-12-04 21:05
1420
Week's Top Stories
Most Reposted
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 293 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
[Picked up by 279 media titles]
2024-11-08 20:11
Most Read
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
2024-11-11 21:00
5646
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
2024-11-08 20:11
5573
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
2024-11-12 09:00
5560
HOIANA RESORT & GOLF LAUNCHES PREMIUM HOIANA PICKLEBALL COURT
2024-11-08 00:18
5536
